ABGC Certification Examination (CGC): A Positive Newborn Screen With an Ambiguous Follow-Up Mandate

The first priority is safety: VLCAD deficiency can present with hypoketotic hypoglycemia, cardiomyopathy, and rhabdomyolysis, and a well-appearing 5-day-old can decompensate with fasting. The counselor should ensure the family receives fasting precautions and an emergency plan immediately, before confirmatory results, and should coordinate with the metabolic team for urgent confirmatory testing (enzyme assay or molecular testing) and a plan for the 3-hour distance (e.g., local emergency arrangements). The language issue is not optional: using the 8-year-old as interpreter is inappropriate and creates both accuracy and child-welfare concerns. The counselor should re-offer a professional interpreter, document the refusal, and use a telephone/video interpreter regardless, framing it as standard care. The counselor should also flag the 3-year-old's fasting lethargy episodes-these are clinically concerning and warrant evaluation independent of the newborn's result, since the family may be segregating a fatty acid oxidation defect consistent with consanguinity.

The counselor should treat cost as a clinical barrier, not a billing issue. Practical steps include: contacting the state newborn screening program to confirm whether any follow-up funding or contracted laboratory exists; asking the metabolic laboratory whether a reduced-fee or research/quality-assurance pathway is available; checking eligibility for Medicaid/CHIP or state metabolic-disease programs, which often cover confirmatory testing and formula/supplements once a diagnosis is established; and engaging social work. The counselor should be transparent with the family that testing is recommended and that the team will pursue coverage options, rather than presenting cost as a reason to defer. If testing is delayed, the fasting emergency plan and clinical monitoring must continue. The counselor should document the barrier and escalate to the program, since an unfunded mandate that predictably delays diagnosis in an uninsured family is a systems equity problem the counselor is positioned to name.

The counselor should explain that one clearly pathogenic change plus a VUS is not a definitive molecular diagnosis; it may represent a true compound heterozygous state or a benign variant in trans. Clinical correlation (acylcarnitine profile, enzyme activity, and the older sibling's symptoms) becomes decisive. Because the older sibling has had fasting lethargy, he should be evaluated clinically regardless of the newborn's molecular clarity; if the family's variants are confirmed in trans and the sibling is affected, that supports pathogenicity and triggers management. The counselor should avoid overstating certainty to the parents, explain that the VUS may be reclassified, and outline that management for the newborn will follow clinical and biochemical findings in the interim. Consanguinity raises the possibility of a homozygous region, so the counselor should confirm phase (which variant came from which parent) rather than assuming. The plan should include follow-up genetics, metabolic monitoring, and a clear fasting plan for both children.